Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes
May 2010
in “
European Journal of Cancer
”
Studysummary This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ejcancer.com →